Literature DB >> 28438617

Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis.

Rocco Cappellesso1, Claudio Luchini2, Nicola Veronese3, Marcello Lo Mele1, Erik Rosa-Rizzotto4, Ennio Guido4, Franca De Lazzari4, Pierluigi Pilati5, Fabio Farinati6, Stefano Realdon7, Marco Solmi8, Matteo Fassan9, Massimo Rugge1.   

Abstract

Worldwide, colorectal cancer (CRC) screening programs have significantly increased the detection of submucosal (pT1) adenocarcinoma. Completion surgery may be indicated after endoscopic excision of these potentially metastasizing early cancers. However, the postsurgical prevalence of nodal implants does not exceed 15%, leading to questions concerning the clinical appropriateness of any post-endoscopy surgery. Eastern scientific societies (Japanese Society for Cancer of the Colon-Rectum, in particular) include tumor budding (TB), defined as the presence of isolated single cancer cells or clusters of fewer than 5 cancer cells at the tumor invasive front, among the variables that must be included in histologic reports. In Western countries, however, no authoritative endorsements recommend the inclusion of TB in the histology report because of the heterogeneity of definitions and measurement methods as well as its apparent poor reproducibility. To assess the prognostic value of TB in pT1 CRCs, this meta-analysis evaluated 41 studies involving a total of 10137 patients. We observed a strong association between the presence of TB and risk of nodal metastasis in pT1 CRC. In comparing TB-positive (684/2401; 28.5%) versus TB-negative (557/7736; 7.2%) patients, the prevalence of nodal disease resulted in an odds ratio value of 6.44 (95% confidence interval, 5.26-7.87; P<.0001; I2 = 30%). This increased risk of regional nodal metastasis was further confirmed after accounting for potential confounders. These results support the priority of histologically reporting TB in any endoscopically removed pT1 CRC to direct more appropriate patient management.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Lymph node metastasis; Meta-analysis; Sprouting; Tumor budding

Mesh:

Year:  2017        PMID: 28438617     DOI: 10.1016/j.humpath.2017.04.013

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  22 in total

1.  Interobserver variability in the H&E-based assessment of tumor budding in pT3/4 colon cancer: does it affect the prognostic relevance?

Authors:  Benedikt Martin; Eva Schäfer; Elzbieta Jakubowicz; Patrick Mayr; Regina Ihringer; Matthias Anthuber; Gerhard Schenkirsch; Tina Schaller; Bruno Märkl
Journal:  Virchows Arch       Date:  2018-04-06       Impact factor: 4.064

2.  Tumor budding is an adverse prognostic marker in intestinal-type sinonasal adenocarcinoma and seems to be unrelated to epithelial-mesenchymal transition.

Authors:  Valeria Maffeis; Rocco Cappellesso; Francesca Galuppini; Vincenza Guzzardo; Alessia Zanon; Diego Cazzador; Enzo Emanuelli; Laura Ventura; Alessandro Martini; Ambrogio Fassina
Journal:  Virchows Arch       Date:  2020-01-24       Impact factor: 4.064

3.  Tumor Budding Detection System in Whole Slide Pathology Images.

Authors:  Mohammad F A Fauzi; Wei Chen; Debbie Knight; Heather Hampel; Wendy L Frankel; Metin N Gurcan
Journal:  J Med Syst       Date:  2019-12-18       Impact factor: 4.460

Review 4.  Tumour budding in solid cancers.

Authors:  Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2020-09-08       Impact factor: 66.675

5.  Tumor Budding as a Marker for Poor Prognosis and Epithelial-Mesenchymal Transition in Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Nishant Thakur; Muhammad Joan Ailia; Yosep Chong; Ok Ran Shin; Kwangil Yim
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

6.  Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma.

Authors:  Ekaterina Petrova; Verena Zielinski; Louisa Bolm; Cleopatra Schreiber; Juliana Knief; Christoph Thorns; Peter Bronsert; Sylvia Timme-Bronsert; Dirk Bausch; Sven Perner; Tobias Keck; Ulrich Wellner
Journal:  Virchows Arch       Date:  2019-11-30       Impact factor: 4.064

Review 7.  Tumour budding and its clinical implications in gastrointestinal cancers.

Authors:  Inti Zlobec; Martin D Berger; Alessandro Lugli
Journal:  Br J Cancer       Date:  2020-06-30       Impact factor: 7.640

8.  Tumour budding in oral squamous cell carcinoma: a meta-analysis.

Authors:  Alhadi Almangush; Matti Pirinen; Ilkka Heikkinen; Antti A Mäkitie; Tuula Salo; Ilmo Leivo
Journal:  Br J Cancer       Date:  2017-11-30       Impact factor: 7.640

9.  Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.

Authors:  Anne Trinh; Claudia Lädrach; Heather E Dawson; Sanne Ten Hoorn; Peter J K Kuppen; Marlies S Reimers; Miriam Koopman; Cornelis J A Punt; Alessandro Lugli; Louis Vermeulen; Inti Zlobec
Journal:  Br J Cancer       Date:  2018-11-02       Impact factor: 7.640

10.  Clinical practice guideline for endoscopic resection of early gastrointestinal cancer.

Authors:  Chan Hyuk Park; Dong-Hoon Yang; Jong Wook Kim; Jie-Hyun Kim; Ji Hyun Kim; Yang Won Min; Si Hyung Lee; Jung Ho Bae; Hyunsoo Chung; Kee Don Choi; Jun Chul Park; Hyuk Lee; Min-Seob Kwak; Bun Kim; Hyun Jung Lee; Hye Seung Lee; Miyoung Choi; Dong-Ah Park; Jong Yeul Lee; Jeong-Sik Byeon; Chan Guk Park; Joo Young Cho; Soo Teik Lee; Hoon Jai Chun
Journal:  Intest Res       Date:  2020-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.